Financial Performance - Revenue for Q1 2022 was ¥600,753,831.09, a decrease of 7.22% compared to ¥647,521,779.69 in the same period last year[4] - Net profit attributable to shareholders was ¥50,204,732.44, down 61.49% from ¥130,373,181.25 year-on-year[4] - Basic earnings per share decreased by 71.19% to ¥0.3130 from ¥1.0864 in the previous year[4] - Total operating revenue for Q1 2022 was CNY 600,753,831.09, a decrease of 7.5% compared to CNY 647,521,779.69 in the same period last year[28] - The net profit for Q1 2022 was CNY 52,632,513.24, a decrease of 59.6% compared to CNY 130,467,736.06 in Q1 2021[30] - The company reported a net profit margin of approximately 10.7% for Q1 2022, down from 12.5% in Q1 2021[28] - Operating profit for Q1 2022 was CNY 59,566,256.94, down 63.1% from CNY 161,416,685.71 in Q1 2021[30] - The company reported a total comprehensive income of CNY 52,632,513.24 for Q1 2022, down from CNY 130,467,736.06 in the previous year[34] Cash Flow and Liquidity - Net cash flow from operating activities was negative at ¥317,768,933.80, a significant decline of 4,479.79% compared to ¥7,255,348.97 in the same period last year[4] - Total operating cash flow was negative at approximately -¥317.77 million, a decrease of 4479.79% compared to the previous period, primarily due to increased procurement costs[10] - The cash flow from operating activities showed a net outflow of CNY 317,768,933.80, compared to a net inflow of CNY 7,255,348.97 in Q1 2021[39] - Cash and cash equivalents decreased to CNY 1,795,982,502.52 from CNY 1,989,232,177.59 at the beginning of the year, a decline of 9.7%[25] - The total cash and cash equivalents at the end of Q1 2022 were CNY 1,730,252,830.26, down from CNY 2,213,913,015.86 at the end of Q1 2021[39] - Financing activities generated a net cash inflow of CNY 273,675,360.54, contrasting with a net outflow of CNY 176,044,056.53 in Q1 2021[39] Assets and Liabilities - Total assets increased by 5.95% to ¥6,152,439,179.75 from ¥5,807,122,186.75 at the end of the previous year[4] - Total liabilities increased to CNY 1,128,556,091.80, a rise of 34.0% from CNY 841,974,541.55 at the start of the year[27] - The company's equity attributable to shareholders rose to CNY 5,004,378,974.99, an increase of 1.2% from CNY 4,947,205,854.71 at the beginning of the year[27] - Non-current assets totaled CNY 1,598,040,668.38, a significant increase of 24.0% from CNY 1,288,258,012.57 at the start of the year[25] Expenses - Total operating costs increased to CNY 536,028,236.07, up 10.2% from CNY 486,315,695.66 in Q1 2021[28] - Sales expenses rose by 30.29% to approximately ¥124.68 million, driven by significant expansion in the hearing aid segment and the acquisition of Jirui Medical[10] - R&D expenses increased by 75.78% to approximately ¥21.10 million, attributed to a rise in personnel and project costs[10] - Research and development expenses increased to CNY 21,100,488.96, up 76% from CNY 12,003,648.26 in the previous year[30] - The company’s management expenses surged by 141.55% to approximately ¥28.21 million, largely due to stock payment expenses and the acquisition of Jirui Medical[10] Acquisitions and Investments - The company acquired 80% of Chengdu Yier Hearing Aid Co., Ltd. for RMB 17.44 million, which has been included in the consolidated financial statements[21] - The company completed the acquisition of 100% of Acorn Trading (Shanghai) Co., Ltd. for RMB 177 million, including related intellectual property rights, and it is now a wholly-owned subsidiary[21] - The company is actively pursuing strategic acquisitions to enhance its market position and expand its product offerings[21] Shareholder Information - The total number of restricted stock granted under the 2021 incentive plan was 375,000 shares, increasing the total share capital from 160 million to 160.375 million shares[21] - The company reported a total of 123,426,040 restricted shares at the end of the reporting period[19] - The top ten shareholders hold a significant portion of unrestricted shares, with the largest being China Construction Bank's fund holding 1,612,897 shares[17] - The company has a total of 65,446,095 restricted shares held by Changsha Medical Investment Co., Ltd., which will be released on April 24, 2025[17] - The company’s major shareholders include Zhang Min and Nie Juan, who collectively control a significant portion of the company[17] - The company has not reported any changes in the number of restricted shares during the reporting period[19] - The company’s stock is subject to various restrictions, with specific release dates for different shareholders[17] Other Financial Metrics - Non-operating income totaled ¥1,870,282.45 after accounting for tax effects and minority interests[5] - The weighted average return on equity decreased by 11.33 percentage points to 1.01% from 12.34%[4] - Deferred income tax liabilities increased by 37.73% to approximately ¥6.01 million, due to temporary differences from fair value changes in financial assets[10] - The company reported a significant increase in investment income of 529.58% to approximately ¥1.49 million, resulting from gains on structured deposits[10]
可孚医疗(301087) - 2022 Q1 - 季度财报